Your New Blockbuster Biotech Stock Profile Is
Pharmagreen Biotech, Inc. (PHBI) January 23rd, 2020 Dan here, your new stock profile (PHBI) is looking stronger pre-market according to level 2 quotestream. Welcome to Pharmagreen Biotech, Inc. Company Overview:
Through our merger with WFS Pharamgreen Inc. (“Pharmagreen” or “The Company”) is headquartered in Coquitlam, British Columbia. Pharmagreens’ mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of high CBD hemp and other flora and offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American high CBD hemp, Cannabis and agriculture sectors.
Its immediate focus will be on producing tissue cultured high CBD hemp starter plantlets. Pharmagreen has applied to Health Canada for a license to produce and sell tissue culture plantlets and cannabis oil. On February 7, 2019, Pharmagreen’s, Canadian subsidiary, WFS Pharmagreen Inc., received notification from Health Canada that its cannabis licensing application under the Cannabis Act and the Cannabis Regulations to obtain a license at the proposed site in Deroche, British Columbia, Canada has advanced from the first stage, “Intake and Screening” to the second stage, “Detailed Review and Initiation of Security Clearance Process,” of a three stage approval process.
The Company is currently completing its engineering stage and has begun site development work for the building process of a 63,000 square foot biotech complex. Pharmgreen is dedicated to becoming an internationally recognized and valued biotech science solutions company in North America for its proprietary micro-propagation techniques, tissue culture plantlets production, research and development for plants sustainability, preservation of genetics, extraction of botanical oils, Cannabis products development, and plant DNA species identification and certification. 5 Key Highlights For Enormous Upside Potential For Shareholders Pharmagreen is headquartered in Deroche, British Columbia. Pharmagreens’ mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of high CBD hemp and other flora and offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American high CBD hemp, Cannabis and agriculture sectors.
The Company is currently completing its engineering stage and has begun site development work for the building process of a 63,000 square foot biotech complex. The Botany Center will serve the following purposes:
- Plantlets tissue culture unit (under Cannabis licence)
- Plantlets low temperature storage unit (under Cannabis licence)
- Plant DNA testing unit (Under Cannabis licence)
- Cannabis and high CBD hemp product development unit (under Cannabis Licence)
- Cannabis and high CBD hemp oil products extraction (under Cannabis Licence)
Pharmagreen is dedicated to become internationally recognized and valued biotech science solutions company in North America for its proprietary micro-propagation techniques, tissue culture plantlets production, preservation of genetics, extraction of cannabis oil, Cannabis and high CBD hemp products development, and plant DNA species identification and certification. The extraction of cannabis oil and new cannabis and high CBD hemp product development If Pharmagreen is awarded Cannabis License with Health Canada it will continue to build out the Biotech Complex. It will take 19 months to construct and make operational the Biotech Complex. Pharmagreen Closes $10 Million Equity Purchase Agreement
CARSON CITY, NV, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce today that the company executed all the required documents for an Equity Purchase Agreement (the "Equity Agreement") with Oscaleta Partners LLC ("Oscaleta"), as stated earlier in the news release dated November 12, 2019, that should enable Pharmagreen to access capital over the next 2 years to support its current growth plans. The terms of the Equity Agreement will give Pharmagreen the right, but never the obligation, to sell to Oscaleta up to Ten Million Dollars’ worth of Pharmagreen’s registered common stock over an anticipated two-year period at times and in amounts that Pharmagreen deems appropriate.
Now that the Equity Agreement is fully executed, the company has started immediate work on the registration statement. The company plans to access the capital for its ongoing project development for state of the art greenhouse and tissue cultured starter plantlets production facility construction. Pharmagreen’s primary use of the facilities is to supply hemp farmers with its “CBD Dana” hemp strain that is a very high yielder of high CBD content biomass and flower tops, please visit our website; www.pharmagreen.ca Peter Wojcik, President and CEO, stated, “Partnering with Oscaleta is significant for the company as we can be concerting on executing our business plan and growing the company, while Oscaleta funding agreements with their years of expertise and established network in the industry provides us with additional support in the financial market.” Commenting on the investment, Stephen Hicks, Manager of Oscaleta, said, "As an institutional investor for more than 20 years, we partner with companies that meet very specific criteria – it boils down to 'how revolutionary is this?' We're excited about the long-term potential." About Oscaleta Partners, LLC Oscaleta Partners, LLC is a diversified financial holding company specializing in direct investment and advisory services to small and middle market companies. Since 1996 the structured finance team has made direct investment of over $1.8 billion into growth companies globally. Our expertise lies in our ability to customize a financing plan for the prospective client and then execute on that plan without fail. Pharmagreen Provides Critical Intel On Future Developments CARSON CITY, NV, Dec. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to provide a company development update. The company has secured significant credit facility to date and plans to use the funds to move forward with its projects development to build a state of the art all year round greenhouse and a tissue cultured starter plantlet production facility. The all year round greenhouse was added to the company’s plans for a first build out as time to complete construction is less than six months and revenue producing within 3 months of operations. The greenhouse will allow the company to earn revenues while the tissue culture facility is under construction.
Due to the extremely long periods of time Health Canada takes to process and issue Cannabis licences, the company has been strategically focused on the supply of its high CBD hemp strain plantlets. This year’s very successful “CBD Dana” hemp pilot project was conducted across Canada by Botanical Research In Motion Inc., (B.R.I.M.), one of Pharmagreen’s strategic partners. The pilot project yielded great results and has proven and validated this strain to be a large producer of CBD biomass with CBD content reaching into double digits while the THC remaining very stable under 0.3% throughout the whole plant cycle. The research from this project is being submitted by B.R.I.M. to Health Canada for further review and for approval for the cultivar status. Changes to Health Canada’s hemp regulations are coming sometime in 2020, but what the changes are remains to be seen. Until then, the current list of 50 plus strains on Health Canada’s approved cultivar list are not worthwhile for CBD hemp farming as stated by the industry experts at the Canadian Hemp Trade Alliance trade show recently held in November, 2019. Getting “CBD Dana” hemp strain on the cultivar list will provide the Canadian Hemp farmers an opportunity to farm with high CBD hemp strain that’s very well suited for the North American growing conditions.
With the passage of the 2018 Farm Bill in U.S., “CBD Dana” hemp strain is now classified as hemp because it meets the requirement of less than 0.3% of THC. The Farm Bill also does not place restrictions for any particular hemp strain that can be grown as long as the content is less than 0.3% THC. This Bill is very positive for the cultivation of hemp and for the production of its cannabinoids based products such as CBD. This makes the U.S. regulatory structure one of the friendliest to grow hemp for high, non-THC cannabinoids production. Combined super-efficient regulations and being the world’s largest economy, U.S. has become a global player in less than a year in hemp production and CBD products development. In summer of 2019, the World Health Organization also stated that CBD should not be considered a controlled substance.
Stay on the look out for more details regarding PHBI Regards, Dan Davis Editor StockStreetWire Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockStreetWire full disclosure is to be read and fully understood before using StockStreetWire website, or joining StockStreetWires' email or text list. By viewing StockStreetWire's website and/or reading StockStreetWire email or text newsletter you are agreeing to StockStreetWire's full disclosure which can be read at stockstreetwire.com/disclosure Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates stock street wire .com ("SSW"). From time to time, non-affiliated third parties hire Stock Wire News, or SSW jointly to publicly disseminate information about a company via website, email, SMS and other points of media .Pursuant to an agreement between StockStreetWire (SSW) and StockWireNews LLC, (a non affiliated 3rd party), SSW has been hired for a period beginning on 1/22/20 and ending on 1/23/20 to publicly disseminate information about (PHBI) via Website, Email and SMS. We have been paid five thousand USD via ACH. We own zero shares of (PHBI). To date, we have been compensated a total of thirty thousand and fifty USD via ACH to disseminate information about (PHBI).
A member of StockWireNews LLC owns an interest in StockStreetWire. Pursuant to an agreement between StockWireNews LLC and Awareness Consulting Network LLC (a non affiliated 3rd party), StockWireNews has been hired for a period beginning on 1/22/20 and ending on 1/23/20 to publicly disseminate information about (PHBI) via Website, Email and SMS. We have been paid thirty-five thousand USD via bank wire transfer. We own zero shares of (PHBI). To date, we have been compensated a total of ninety-five thousand USD via bank wire transfer to disseminate information about (PHBI). No compensation, DINO, BTLN, VMHG, AEPT, FULO, ITRK, SNWR, CLTH, ESYL, BEGI Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates stock street wire .com ("SSW"). From time to time, non-affiliated third parties hire Stock Wire News, or SSW jointly to publicly disseminate information about a company via website, email, SMS and other points of media.
Pursuant to an agreement between Stock Street Wire (SSW) and StockWireNews LLC, (a non affiliated 3rd party), SSW has been hired for a period beginning on 1/14//20 and ending on 1/15/20 to publicly disseminate information about (GAXY) via Website, Email and SMS. SSW has been paid seven thousand five hundred USD via ACH. We own zero shares of (GAXY).
|
| | |
